China Isotope & Radiation Corporation (HKG:1763)

Market Cap	7.02B +111.0%
Revenue (ttm)	8.35B +13.7%
Net Income	464.77M +6.0%
EPS	1.45 +6.0%
Shares Out	319.87M
PE Ratio	15.10
Forward PE	n/a
Dividend	0.43 (1.98%)
Ex-Dividend Date	Oct 21, 2025

Volume	53,200
Average Volume	158,370
Open	22.12
Previous Close	21.94
Day's Range	21.90 - 22.20
52-Week Range	10.38 - 25.00
Beta	0.59
RSI	48.47
Earnings Date	Mar 27, 2026

About China Isotope & Radiation

China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of nuclides, diagnostic, and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Other Businesses. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmace...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1983
• Employees: 3,361
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1763

Financial Performance

In 2024, China Isotope & Radiation's revenue was 7.57 billion, an increase of 14.16% compared to the previous year's 6.63 billion. Earnings were 406.65 million, an increase of 9.62%.

Financial numbers in CNY